Khalid El Bairi

List of Publications by Year
in descending order

48 papers	3,042 citations	516710 16 h-index	361022 35 g-index
52 all docs	52 docs citations	52 times ranked	3384 citing authors

#	Article	IF	Citations
1	Natural products in drug discovery: advances and opportunities. Nature Reviews Drug Discovery, 2021, 20, 200-216.	46.4	1,990
2	The path to a better biomarker: application of a risk management framework for the implementation of PD‑L1 and TILs as immuno‑oncology biomarkers in breast cancer clinical trials and daily practice. Journal of Pathology, 2020, 250, 667-684.	4.5	142
3	The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group. Npj Breast Cancer, 2021, 7, 150.	5.2	112
4	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. Npj Breast Cancer, 2020, 6, 17.	5.2	106
5	Toxicological properties of fenugreek (Trigonella foenum graecum). Food and Chemical Toxicology, 2016, 96, 145-154.	3.6	93
6	Report on computational assessment of Tumor Infiltrating Lymphocytes from the International Immuno-Oncology Biomarker Working Group. Npj Breast Cancer, 2020, 6, 16.	5.2	90
7	Natural products against cancer angiogenesis. Tumor Biology, 2016, 37, 14513-14536.	1.8	76
8	Repurposing anticancer drugs for the management of COVID-19. European Journal of Cancer, 2020, 141, 40-61.	2.8	59
9	Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer. Cellular Oncology (Dordrecht), 2017, 40, 105-118.	4.4	42
10	Decoding colorectal cancer epigenomics. Cancer Genetics, 2018, 220, 49-76.	0.4	42
11	Anticancer potential of Trigonella foenum graecum: Cellular and molecular targets. Biomedicine and Pharmacotherapy, 2017, 90, 479-491.	5.6	39
12	Prediction of therapy response in ovarian cancer: Where are we now?. Critical Reviews in Clinical Laboratory Sciences, 2017, 54, 233-266.	6.1	28
13	The arrival of predictive biomarkers for monitoring therapy response to natural compounds in cancer drug discovery. Biomedicine and Pharmacotherapy, 2019, 109, 2492-2498.	5.6	24
14	Plasminogen Activator System and Breast Cancer: Potential Role in Therapy Decision Making and Precision Medicine. Biomarker Insights, 2016, 11, BMI.S33372.	2.5	23
15	The Emerging Role of Liquid Biopsy in Gastric Cancer. Journal of Clinical Medicine, 2021, 10, 2108.	2.4	20
16	Phytochemical, organoleptic and ferric reducing properties of essential oil and ethanolic extract from Pistacia lentiscus (L.). Asian Pacific Journal of Tropical Disease, 2016, 6, 305-310.	0.5	19
17	Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials. Npj Breast Cancer, 2020, 6, 15.	5.2	16
18	FGFR Pathway Inhibition in Gastric Cancer: The Golden Era of an Old Target?. Life, 2022, 12, 81.	2.4	15

#	Article	IF	Citations
19	Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of outcomes in inflammatory breast cancer. Biomarkers in Medicine, 2021, 15, 1289-1298.	1.4	12
20	Inexpensive Systemic Inflammatory Biomarkers in Ovarian Cancer: An Umbrella Systematic Review of 17 Prognostic Meta-Analyses. Frontiers in Oncology, 2021, 11, 694821.	2.8	11
21	Revisiting antibody-drug conjugates and their predictive biomarkers in platinum-resistant ovarian cancer. Seminars in Cancer Biology, 2021, 77, 42-55.	9.6	10
22	The global landscape of availability, accessibility and affordability of essential diagnostics and therapeutics for the management of HER2-positive breast cancer: The ONCOLLEGE-001 survey. Journal of Cancer Policy, 2021, 28, 100285.	1.4	9
23	Starvation tactics using natural compounds for advanced cancers: pharmacodynamics, clinical efficacy, and predictive biomarkers. Cancer Medicine, 2018, 7, 2221-2246.	2.8	8
24	Can the microbiota predict response to systemic cancer therapy, surgical outcomes, and survival? The answer is in the gut. Expert Review of Clinical Pharmacology, 2020, 13, 403-421.	3.1	7
25	Does the "Devil" originate from the fallopian tubes?. Seminars in Cancer Biology, 2021, 77, 56-66.	9.6	7
26	Role of Her-2 in Gastrointestinal Tumours beyond Gastric Cancer: A Tool for Precision Medicine. Gastrointestinal Disorders, 2021, 3, 1-22.	0.8	7
27	Tracing ovarian cancer research in Morocco: A bibliometric analysis. Gynecologic Oncology Reports, 2021, 37, 100777.	0.6	6
28	Is HE4 Superior over CA-125 in the Follow-up of Patients with Epithelial Ovarian Cancer?. Current Drug Targets, 2020, 21, 1026-1033.	2.1	6
29	Bevacizumab in metastatic colorectal cancer in a real-life setting – toxicity profile, survival outcomes, and impact of tumor sidedness. Wspolczesna Onkologia, 2022, 26, 32-39.	1.4	5
30	The Human Cancer Pathology Atlas: An open-access source for more than 900,000 Kaplan-Meier plots and 5 million cancer tissue images. Biomedicine and Pharmacotherapy, 2017, 96, 1438-1439.	5.6	4
31	Revisiting platinum-resistant ovarian cancer: Advances in therapy, molecular biomarkers, and clinical outcomes. Seminars in Cancer Biology, 2021, 77, 1-2.	9.6	2
32	Practical Tools and Guidelines for Young Oncologists From Resource-Limited Settings to Publish Excellence and Advance Their Career. JCO Global Oncology, 2021, 7, 1668-1681.	1.8	2
33	Painting the global picture of HER2-testing for breast cancer. The ONCOLLEGE-001 survey study. Annals of Oncology, 2019, 30, iii14.	1.2	1
34	Ovarian cancer in Morocco: Time to act is now. Gynecologic Oncology Reports, 2021, 37, 100857.	0.6	1
35	The Power of Biomarkers in Transforming Patients Care in Gynecologic Oncology. Current Drug Targets, 2020, 21, 944-945.	2.1	1
36	Gut Microbiota, Next-Generation Sequencing, Immune-Checkpoint Inhibitors, and Colorectal Cancer: How Hot Is the Link?. , 2020, , 111-145.		1

#	Article	IF	Citations
37	Colorectal Cancer Genetics: An Overview of the Actionable Building Blocks. , 2020, , 29-71.		1
38	The Revolution of Liquid Biopsy and Single-Cell Sequencing in the Management of Colorectal Cancer. , 2020, , 147-172.		1
39	Accessibility and affordability to trastuzumab for breast cancer patients: Voices of the global oncology community from ONCOLLEGE 001 survey, part 2. Annals of Oncology, 2019, 30, v673.	1.2	0
40	Illuminating Colorectal Cancer Genomics by Next-Generation Sequencing. , 2020, , .		0
41	Genetic Alterations in Ovarian Cancer as Prognostic and Predictive Biomarkers of Therapy Response and Surgical Outcomes. , 2021, , 135-166.		0
42	Cutting-Edge Technologies for Ovarian Cancer: An Overview of the Impact of Genetic Testing, Next-Generation Sequencing, and Single-Cell Analysis. , 2021, , 203-229.		0
43	The Hallmarks of Ovarian Cancer: Actionable Genetics, Targetable Pathways, and Predictive Biomarkers. , 2021, , 59-133.		0
44	Origins and Pathology of Epithelial Ovarian Cancer: A Brief Overview. , 2021, , 1-17.		0
45	The Advent of Circulating Tumor DNA in the Management of Ovarian Cancer. , 2021, , 167-185.		0
46	Overview of Cost-Effectiveness and Limitations of Next-Generation Sequencing in Colorectal Cancer. , 2020, , 173-185.		0
47	Next-Generation Sequencing for Colorectal Cancer Management. , 2020, , 91-110.		0
48	How to critically read a meta-analysis of clinical trials in neurooncology. International Journal for Research and Ethics, 2022, 5, .	0.0	0